Jump to content

Draft:Atai Life Sciences

From Wikipedia, the free encyclopedia
  • Comment: There are a lot of references on funding but I do not see anything in a search that meets WP:ORGCRIT. In addition, this draft needs to be written more like an encyclopedia page instead of a brochure for the company. Wording such as this ("Atai incorporates a model of developing some assets in house, its primarily employing a “buy and build” strategy where it acquires controlling stakes in early-stage companies") is purely promotion and looks like it was written by someone from the company itself. CNMall41 (talk) 00:38, 5 July 2021 (UTC)

atai Life Sciences
NASDAQ: ATAI
Company typePublic
IndustryHealthcare
Founded2018
HeadquartersBerlin, Germany
Key people
Christian Angermayer, Florian Brand, Lars Christian Wilde, Srinivas Rao
Websiteatai Life Sciences

Atai Life Sciences is a clinical-stage biopharmaceutical company that leverages alternative treatments for mental health disorders. Founded in 2018 and headquartered in Berlin, it has additional offices in New York and London. The company uses a decentralised, technology and data-driven platform model working with various psychedelic compounds such as Psilocybin, R-ketamine and Ibogaine to treat mental health disorders such as depression, anxiety, PTSD and addiction.

History

[edit]

The company was founded in 2018 by Christian Angermayer, Florian Brand, Lars Christian Wilde, Srinivas Rao. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange[1].

Atai incorporates a model of developing some assets in house, its primarily employing a “buy and build” strategy where it acquires controlling stakes in early-stage companies. Thus far company has acquired 3 organisations, their most recent acquisition was Psyber on Apr 7, 2021.[2] These operate as subsidiaries with a shared operational backbone. The first of atai’s psychedelic programs was embodied in Compass Pathways (NASDAQ: CMPS), which conducted an IPO in September of 2020 was valued at over $1.3B as of November 2020.[3]

References

[edit]
  1. ^ Ponieman, Natan (14 June 2021). "Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers". finance.yahoo.com. Retrieved 2021-06-24.
  2. ^ Shead, Sam (9 April 2021). "Peter Thiel-backed firm takes majority stake in a brain computer interface start-up". CNBC. Retrieved 2021-06-19.
  3. ^ Woolley, Suzanne (18 September 2020). "'Magic Mushroom' Company Goes Mainstream, Jumps 71% Post-IPO". www.bloomberg.com. Retrieved 2021-06-19.